Xencor (XNCR) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Xencor (XNCR)

XNCR 14.37

+5.0%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: fitzdad55 who wrote (72)	12/22/2014 5:02:00 PM
From: scaram(o)uche	Read Replies (1) of 136

Sort of tight on time for a few days, maybe you can help me answer. I've landed on their website several times, but am still not certain what they do. Do they specialize in multivalent just for the sake of being multivalent? Interesting company, thanks for pointing. If you can point to a paper or two which describe their methods and objectives, that might help. Otherwise, I'll try to remember to poke around the website with more gusto. Thanks. Investment speaking, bispecifics have interest to me only when a company can combine them with novel Fc engineering. It's a rather old concept, and companies have to avoid going for dime-a-dozen projects. The competition is tough..... adimab.com Adimab Announces 50th Therapeutic Program Under Its Funded Discovery Partnerships Lebanon, NH – June 20, 2014

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next